It will be crucial to investigate MYC alterations in FGFR3 aberrant urothelial bladder cancer, as it may provide further insight into the pathogenesis of bladder cancer, and it could also have therapeutic implications. This evidence concerns the gene FGFR3 and bladder transitional cell carcinoma.